CHP Saint Grégoire

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Prostate cancer4 trials
• Bladder cancer1 trial
• Obesity1 trial
• Osteoarthritis1 trial
• Pancreatic cancer1 trial

Phase

• Phase 22 trials
• Phase 32 trials

Status

• Active, not recruiting4 trials
• Completed3 trials
• Not yet recruiting1 trial

Lead sponsor

• UNICANCER3 trials
• IHU Strasbourg1 trial
• Institut de Cancérologie de Lorraine1 trial
• Institut Paoli-Calmettes1 trial
• Medacta International SA1 trial
• and 1 more

Running trials

• Recruiting

  Endoscopic Sleeve Gastroplasty (ESG) Prospective Trial for Obesity (EGO-Trial)

  NCT07449520· IHU Strasbourg· Source

  Contact: Adrien STERKERS

• Active, not recruiting

  Prostate-cancer Treatment Using Stereotactic Radiotherapy for Oligometastases Ablation in Hormone-sensitive Patients

  NCT04115007· Phase 3· UNICANCER· Source

• Active, not recruiting

  GMK-UNI Anatomical UKA: Fixation of Cemented vs Cementless Designs

  NCT03522025· Medacta International SA· Source

• Active, not recruiting

  Adjuvant Radiotherapy in Patients With Pathological High-risk Bladder Cancer (GETUG-AFU 30)

  NCT03333356· UNICANCER· Source

• Active, not recruiting

  A Phase III Study for Patients With Metastatic Hormone-naïve Prostate Cancer

  NCT01957436· Phase 3· UNICANCER· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Obesity1 recruiting

Closed trials

• Completed

  Evaluation of Hypnosis in Virtual Reality on the Anxiety of Patients With Metastatic Prostate Cancer Over Chemotherapy

  NCT04533958· Saint-Gregoire Private Hospital Center· Source

• Completed

  Active Surveillance With or Without Apalutamide Treatment in Low Risk Prostate Cancer

  NCT03088124· Phase 2· Institut Paoli-Calmettes· Source

• Completed

  Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44)

  NCT02676349· Phase 2· Institut de Cancérologie de Lorraine· Source